Xing et al., 2012 - Google Patents
Genetic evidence that thyroid hormone is indispensable for prepubertal insulin‐like growth factor–I expression and bone acquisition in miceXing et al., 2012
View HTML- Document ID
- 1229371983378783862
- Author
- Xing W
- Govoni K
- Donahue L
- Kesavan C
- Wergedal J
- Long C
- Bassett J
- Gogakos A
- Wojcicka A
- Williams G
- Mohan S
- Publication year
- Publication venue
- Journal of bone and mineral research
External Links
Snippet
Understanding how bone growth is regulated by hormonal and mechanical factors during early growth periods is important for optimizing the attainment of peak bone mass to prevent or postpone the occurrence of fragility fractures later in life. Using genetic mouse models that …
- 239000005495 thyroid hormone 0 title abstract description 165
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xing et al. | Genetic evidence that thyroid hormone is indispensable for prepubertal insulin‐like growth factor–I expression and bone acquisition in mice | |
| Kegelman et al. | Skeletal cell YAP and TAZ combinatorially promote bone development | |
| Neve et al. | Osteocalcin: skeletal and extra‐skeletal effects | |
| O’Shea et al. | A thyrotoxic skeletal phenotype of advanced bone formation in mice with resistance to thyroid hormone | |
| Yasoda et al. | Overexpression of CNP in chondrocytes rescues achondroplasia through a MAPK-dependent pathway | |
| Hesse et al. | Zfp521 controls bone mass by HDAC3-dependent attenuation of Runx2 activity | |
| Govoni et al. | Disruption of insulin-like growth factor-I expression in type IIαI collagen-expressing cells reduces bone length and width in mice | |
| Xi et al. | IGFBP‐2 directly stimulates osteoblast differentiation | |
| Wu et al. | Insulin-like growth factor-independent effects of growth hormone on growth plate chondrogenesis and longitudinal bone growth | |
| Yao et al. | Overexpression of secreted frizzled‐related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects | |
| Watkins et al. | Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling | |
| Xu et al. | Circadian clock regulates bone resorption in mice | |
| Jonason et al. | Post-translational regulation of Runx2 in bone and cartilage | |
| Pierroz et al. | Deletion of β‐adrenergic receptor 1, 2, or both leads to different bone phenotypes and response to mechanical stimulation | |
| Joung et al. | MSM enhances GH signaling via the Jak2/STAT5b pathway in osteoblast-like cells and osteoblast differentiation through the activation of STAT5b in MSCs | |
| Miranda et al. | Effects of resveratrol on changes induced by high-fat feeding on clock genes in rats | |
| Monfoulet et al. | Thyroid hormone receptor β mediates thyroid hormone effects on bone remodeling and bone mass | |
| Xing et al. | Targeted disruption of leucine‐rich repeat kinase 1 but not leucine‐rich repeat kinase 2 in mice causes severe osteopetrosis | |
| Elis et al. | Elevated serum levels of IGF‐1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF‐1 | |
| Syed et al. | Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways | |
| Sher et al. | Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted disruption of glucocorticoid signaling | |
| Sun et al. | Regulation of body length and bone mass by Gpr126/Adgrg6 | |
| Ge et al. | Discoidin receptor 2 controls bone formation and marrow adipogenesis | |
| McGregor et al. | Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling | |
| Kim et al. | Targeted disruption of nuclear factor erythroid-derived 2-like 1 in osteoblasts reduces bone size and bone formation in mice |